Novartis is abandoning trials of its asthma drug fevipiprant, a blow to hopes for a pioneering new way to treat the disease
Novartis AG said it was abandoning a potential blockbuster drug in asthma after it failed two late stage-trials, dealing a blow to the company’s hopes of pioneering a novel way to treat the respiratory disease.
The Swiss health-care giant said the experimental treatment, called fevipiprant, performed no better than a placebo in reducing exacerbations—episodes where symptoms suddenly worsen—in two large trials on patients with moderate to severe asthma.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Novartis drops asthma drug fevipiprant after trial failuresSwiss drugmaker Novartis on Monday said it is jettisoning what it had hoped woul...
Consulte Mais informação »
Eye Drops for Dry Eyes: What Are Your Options?The best eye drops for you may depend on what’s drying your eyes out. Find out which brands work and which you should avoid.
Consulte Mais informação »
Novartis drops asthma drug fevipiprant after trial failuresSwiss drugmaker Novartis on Monday said it is jettisoning what it had hoped woul...
Consulte Mais informação »
Novartis to abandon development of asthma drug after trial failuresSwiss drugmaker Novartis is abandoning development of its drug fevipiprant in as...
Consulte Mais informação »
Nightmare debut for Gattuso as Napoli suffer late loss to ParmaNapoli coach Gennaro Gattuso suffered a disappointing debut as Gervinho's s...
Consulte Mais informação »